Validation of Pharmacokinetic and Pharmacodynamic Assays for determination of Nivolumab and Pembrolizumab concentrations, and the occupancy of their target receptor Programmed Death-1 (PD-1) on T-cells
Recruiting
- Conditions
- metastasized cancerSolid tumors10027476
- Registration Number
- NL-OMON47401
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
Patients with solid tumors who will start treatment with nivolumab or pembrolizumab and are willing to undergo blood sampling and/or donate residual material.
Exclusion Criteria
Patients with known alcoholism, drug addiction, psychotic disorders in the history and/or other reasons, for which they are not amendable for adequate follow up.
Uncontrolled infectious disease or known HIV-1 or HIV-2 type patients.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method